Wistar scientist awarded American Cancer Society grant for research on tumor killing cells

May 10, 1999

Philadelphia-- Daniela Santoli, Ph.D., a professor in The Wistar Institute's Tumor Immunology Program, has been awarded a $300,000 two-year grant from the American Cancer Society for a Phase I/II trial of TALL-104 cells in patients with metastatic melanoma.

TALL-104 is a "killer" cell line derived from the cells of a child with a rare form of T-cell leukemia. Dr. Santoli has found that TALL-104 cells can recognize and selectively kill malignant cells. Her research team has used TALL-104 cells to treat pet dogs and cats with various terminal cancers that were unresponsive to conventional therapy. In many of these companion animals, the TALL-104 cells caused complete, long-lasting remissions.

Phase I clinical trials of TALL-104, which tested the safety of the treatment on humans and established safe dosage ranges for further efficacy trials, were conducted on children with advanced cancers and women with metastatic breast cancer. In these trials, no toxicity was shown up to the planned maximum dose. With the recently awarded American Cancer Society funds, Dr. Santoli and her clinical collaborator, Dr. Lynn Schuchter at the Cancer Center of the Hospital of the University of Pennsylvania, will focus on the development of a TALL-104 regimen that will be effective and safe in melanoma patients with metastatic disease. These trials are not expected to start until later this year.

The American Cancer Society is the nationwide, community-based voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives and diminishing suffering from cancer through research, education, advocacy and service. Last year, the American Cancer Society contributed $93.3 million to research facilities throughout the country.

The Wistar Institute, established in 1892, was the first independent medical research facility in the country. For more than 100 years, Wistar scientists have been making history and improving world health through their development of vaccines for diseases that include rabies, German measles, infantile gastroenteritis (rotavirus), and cytomegalovirus; discovery of molecules like interleukin-12, which are helping the immune system fight bacteria, parasites, viruses and cancer; and location of genes that contribute to the development of diseases like breast, lung and prostate cancer. Wistar is a National Cancer Institute Cancer Center.

The Wistar Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.